Publication | Closed Access

The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment

Pd-l1 Sirna BoostsBreast OncologyImmunologyImmune Checkpoint InhibitorBreast CancerTumor TargetingTriple-negative Breast CancerImmunotherapyMedicineCell BiologyTumor MicroenvironmentProgrammed Site-specific Delivery